Table 4.
Clinical features of the BRCAX cohort, PCOR cohort and BRCA2 cohort.
| BRCAX (n = 111) | PCOR1 (n = 39,953) | BRCA2 (n = 40) 1 | |
|---|---|---|---|
| Age at Diagnosis | 62.7 (mean) 62 (median) 42–84 (range) 9.7 (SE) |
68 (median) | 65.9 (mean) 64.95 (median) |
| PSA pre-diagnosis, n (%) | |||
| <4 ng/mL | 17 (15.3%) | 955 (13%) | 1 (2.5%) |
| 4–10 ng/mL | 43 (38.7%) | 4111 (56%) | 10 (25%) |
| 10+ ng/mL | 25 (22.5%) | 2225 (31%) | 14 (35%) |
| Unknown | 26 (23.4%) | 1067 (14%) | 11 (27.5%) |
| ISUP Grade Group at Diagnosis, n (%) | |||
| 1 | 19 (17.1%) | 2115 (26%) | 2 (5.3%) |
| 2 | 32 (28.8%) | 2606 (32%) | 11 (28.9%) |
| 3 | 23 (20.7%) | 11,380 (7%) | |
| 4 & 5 | 34 (30.6%) | 2002 (25%) | 25 (65.8%) |
| Unknown | 3 (2.7%) | 255 (4%) | - |
| D’Amico Risk Group at Diagnosis | |||
| Low | 21 (18.9%) | 1492 (20%) | 3 (7.7%) |
| Intermediate | 31 (27.9%) | 3454 (46%) | 5 (12.8%) |
| High or very high | 59 (53.2%) | 1832 (25%) | 31 (79.5%) |
| Survival Status | |||
| Deceased n (%) | 30 (27%) | - | 23 (57.5) |
| PCa-specific death (n) | 24 (21.6%) | - | 21 (52.5%) |
| Mean, median years of follow up from diagnosis (range) | 9.5, 8.6 (0.2–26.3) | – | 4.6 years (high risk)9 years (int. risk) |
| Mean, median duration to death (years) | 9.9, 8.8 (0.9–26.3) | – | 4.5 (mean) |
| PCa-specific survival estimate | 91% 5-yr (84–96) | 95% 5-yr (2012–2016) 2 | 33% 15-yr (int. risk) |
| PCa-specific survival estimate | 85% 10-yr (76–91) | 91.3% 10-yr (2011–2015) 3 | 0% 15-yr (high risk) |
1BRCA2 cohort previously described in Bolton et al. BJU Int. 2015, 116, 207–212 [17]. 2 https://www.canceraustralia.gov.au/cancer-types/prostate-cancer/statistics (accessed on 10 September 2021); 3 https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/10-year-relative-survival (accessed on 10 September 2021).